The present invention relates to combination therapies useful for the treatment of cancer. In particular, the invention relates to the treatment of pancreatic cancer using an antagonist of a Programmed Death 1 protein (PD-1) in combination with a live attenuated recombinant Listeria strain comprising a fusion protein of a PEST sequence-containing polypeptide fused to a tumor-associated antigen.本發明係關於適用於治療癌症之組合療法。特定言之,本發明係關於使用計劃性死亡1蛋白(PD-1)之拮抗劑與活減毒重組李斯特菌屬菌株組合治療胰臟癌,該重組李斯特菌屬菌株包含有含PEST序列之多肽與腫瘤相關抗原融合的融合蛋白。